Porcine reproductive and respiratory syndrome virus (PRRSV) infection is difficult to control because the virus undergoes antigenic variation during infection and also modulates the protective host immune response. Although current vaccines do not provide full protection, they have provided insight into the mechanisms of protection. Live PRRSV vaccines induce partial protection before the appearance of neutralizing antibody, suggesting cell-mediated immunity or other mechanisms may be involved. Herein, we demonstrate recovery from infection is associated with development of cytotoxic T-lymphocytes (CTL) that can kill PRRSV-infected target cells. Initial experiments showed survival of PRRSV-infected monocyte derived macrophage (MDM) targets is reduced when overlaid with peripheral blood mononuclear cells (PBMC) from gilts that had recovered from PRRSV infection. These findings will be useful for evaluating CTL responses induced by current and future vaccines, guiding to a novel direction for future vaccine development.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) infection is difficult to control because the virus undergoes antigenic variation during infection and also modulates the protective host immune response. Although current vaccines do not provide full protection, they have provided insight into the mechanisms of protection. Live PRRSV vaccines induce partial protection before the appearance of neutralizing antibody, suggesting cell-mediated immunity or other mechanisms may be involved. Herein, we demonstrate recovery from infection is associated with development of cytotoxic T-lymphocytes (CTL) that can kill PRRSV-infected target cells. Initial experiments showed survival of PRRSV-infected monocyte derived macrophage (MDM) targets is reduced when overlaid with peripheral blood mononuclear cells (PBMC) from gilts that had recovered from PRRSV infection. 
Introduction
Porcine reproductive and respiratory syndrome (PRRS) is one of the most important porcine diseases with a major economic impact, causing more than $600 million per year of direct loss in the USA [1, 2] . PRRS virus is in the genus arterivirus and family arteriviridae, and has a single strand~15 Kb RNA genome encoding at least 10 open reading frames (ORFs 1a, 1b, 2a, 2b, 3, 4, 5, 5a, 6 and 7) [3, 4] . Increasing genetic diversity among recently isolated PRRSVs [3, 5, 6] and the emergence of highly pathogenic PRRSVs in different geographical regions [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] present a tremendous challenge to the control of PRRSV using currently available vaccines. Two conventional vaccine formats, inactivated and live attenuated virus are currently in use, but neither of the vaccines induce satisfactory protection [19] [20] [21] . Inactivated PRRSV vaccines induce weak neutralizing antibody responses against only homologous strains of PRRSV, and thus have poor efficacy in porcine herds infected with genetically diverse variants of PRRSV [22] . Live attenuated PRRSV vaccines are reported to contribute to the reduction of PRRS diseases without preventing infection. Although potentially useful, the high probability of mutation resulting in reversion to virulence in vaccinated herds has been debating as a concern on use of attenuated viruses as a vaccine [8, 23, 24] . Therefore, there is a need to develop safer and more efficacious vaccines that induce protective immune responses against diverse PRRSVs.
Correlates of adaptive immune protection against PRRSV need to be systematically defined in PRRSV-infected and vaccinated pigs. Passive transfer of hyper-immune anti-PRRSV serum with neutralizing antibody activity to naïve pigs contributed to reducing the viral load in plasma in comparison with controls challenged with the homologous strain of PRRSV. However, presence of passively transferred antibody did not affect viral replication in tissues [25] . Low titer neutralizing antibodies produced in infected pigs were not able to control infection with PRRSV [26] [27] [28] [29] . This weak potency of neutralizing antibodies was also restricted to homologous virus in PRRSV-infected pigs, limiting the potential for inducing protection against heterologous virus challenge [30]. Several studies have reported that immunization with live attenuated and killed virus vaccines reduced clinical disease and/or viremia after PRRSV infection before the appearance of neutralizing antibody in serum, suggesting appearance of other mechanisms of protection early in the course of infection [31] [32] [33] [34] . Cell-mediated immunity (CMI) has been proposed as a protective mechanism in vaccinated pigs [34] [35] [36] [37] . Studies to date have identified T-cell epitopes in several PRRSV proteins (e.g., M, N, GP3, GP4, GP5, NSP2, NSP5 and NSP9) using cytokine-based assays and synthetic peptides to stimulate effector cells [36, [38] [39] [40] [41] [42] [43] . T-lymphocytes that recognize these epitopes could be providing protection through targeted killing of infected cells in tissues that have not been cleared by neutralizing antibodies. However, there has been no demonstration that specific porcine Tlymphocytes can kill PRRSV-infected cells. Therefore, approaches are needed to define the relative contribution of mechanisms of adaptive immunity, such as CMI, which could form the basis for future vaccine development, aimed at providing immune protection against diverse PRRSVs.
Multiple CMI assays, such as interferon gamma enzyme-linked immunosorbent spot (ELISpot) assay and intracellular staining (ICS) assay of cytokines, have been used to evaluate the immune response to PRRSV [33, 34, 38] . Assays detecting cytokines as the readout can evaluate an early activation step of PRRSV-specific T-lymphocytes, but cannot reveal development of terminal antiviral activity, such as the cytolysis of PRRSV-infected cells or suppression of PRRSV replication in target cells. The inability to directly measure protective mechanisms against virus infection is a major drawback to using cytokine assays to evaluate immune responses [44, 45] . The proliferation of T-lymphocytes as the readout of PRRSV-specific CMI responses may be a better approach for detection of effector function than cytokine production. However, the limitations of proliferation-based T-lymphocyte assays have been lower sensitivity/specificity and the need for use of radioisotopes to increase the sensitivity. Thus, assays for measuring terminal CMI effector functions in PRRSV-infected target cells will be critical for defining the presence and efficacy of PRRSV-specific CMI responses.
Two assays were developed in the present study, a virus suppression assay which measures the reduction of PRRSV-infected target cells mediated by effector cells and a cytotoxic T-lymphocyte (CTL) assay that measures the direct killing of PRRSV-infected cells, using monocytederived macrophages (MDMs) as target cells and T-cells as effector cells. These assays were used to test the hypothesis that recovery from clinical PRRS disease is associated with development of CTL with the capacity to kill PRRSV-infected cells.
Results

Peripheral blood mononuclear cells (PBMC) from gilts that had recovered from infection by PRRSV reduce the number of PRRSV-infected MDM
A flow cytometry-based virus suppression assay was developed initially to determine whether the reduction in virus replication in MDM target cells is mediated by specific effector cells that disrupt replication by killing the infected cells. Gilt-2 PBMC effector cells at 5:1 effector to target ratio reduced autologous PRRSV-infected MDM in one experiment by 80.8% ( Fig 1A) and in another experiment by 95.5% (Fig 2, lower panel, gilt-2 PBMC effector). Gilt-2 PBMC also caused an 88.0% reduction of PRRSV-infected MDM from a MHC-matched heterologous uninfected gilt-678 (Fig 1B) .
The suppression assay was also used to evaluate PBMC from two other PRRSV-infected gilts 
Identification of T-cell subpopulations causing reduction of PRRSVinfected MDM
The initial experiments with the suppression assay were conducted with effector cells from gilt-2, using total PBMC, CD8 + T-cell-depleted PBMC, and positively selected CD8 + T-cells.
Both total PBMC and CD8 + T-cell-depleted PBMC (at 5:1 effector to target ratio) reduced the number of PRRSV-infected MDM by 95% (Fig 2, lower 
T-cells expressing granzyme-B and kill infected MDM
The data obtained from the suppression assay suggested that suppression was mediated by direct killing of infected target cells by cytotoxic T-lymphocyte (CTL). To explore this possibility, a flow cytometric assay was developed, based on the use of fluorescent dye (TFL4) that labels the infected target cells and a fluorogenic PanToxiLux substrate (PS) for granzyme B and upstream caspase [46, 47] with PRRSV, which was much higher than the 5.38% in the MDM at 0 hpi (Fig 4, left three panels). Furthermore, gilt-2 CTL also recognized epitopes presented on PRRSV-infected MDM at 3 hpi which was possibly before de novo synthesis of viral proteins. This cytotoxicity T-cells were increased at 3 hpi (11.0%) and 24 hpi (12.04%) compared to 0 hpi (3.82%) (Fig 4,  center panels) . These results demonstrated that both CD4 + and CD8 + gilt-2 T-cells expressed granzyme-B while killing PRRSV-infected MDM (Fig 4, left panels) . ) was biphasic with a moderate peak (10.7%) at 3 hpi followed by a drop at 12 hpi (6.3%), and a second, major peak starting at 18 hpi (13.9%) to 24 hpi (17.1%) (Fig 5A) . Similar results were obtained with heterologous, MHC-matched, PRRSV-infected MDM (Fig 5B) . Together these results demonstrated that CTL epitope expression varied in MDM over 24 hpi, as the same effector cells were used for each time point.
Different T-cell subpopulations had unique recognition patterns of PRRSV-infected MDM
The highest percentages of activated CD8 +high PS + T-cells were at 3 and 6 hpi with a subsequent decrease so that by 24 hpi the percentage was the same as 0 hpi (Fig 5A & 5B) . This monophasic response of CD8 +high PS + T-cells was in contrast to the biphasic recognition that occurred with the CD4 + PS + CTL ( Fig 5A & 5B) ; a peak was observed at 3 hpi and another higher peak at 24 hpi (Fig 5A & 5B) respectively). These data demonstrated that some killing of MDM target cells at 3 hours after PRRSV infection was caused by CD8 + CTL from gilt-2, but that these CTL were not the major T-cell subpopulation involved in the killing at this time point. ) with killing activity at the different time points examined during the 24-hour time frame of the study. The gating strategy described in Fig 7C was used to (Fig 7A & 7B) . Control of PRRSV by CTL
Identification of the predominant T-cell phenotypes with granzyme-B in the cytotoxic assay using MDM infected with PRRSV at different times
Discussion
The replication of PRRSV after entry into macrophages using CD163 as receptors [48] [49] [50] [51] causes immune modulations in pigs, resulting in weak adaptive immune responses as well as persistence of the virus [38, 52, 53] . In spite of these challenges, PRRSV in blood, lung and lymphoid tissues of infected pigs is occasionally controlled before appearance of virus-specific neutralizing antibodies and this phenomenon strongly suggests a contribution of CMI in controlling the virus [31] [32] [33] [34] .
In this study, a virus suppression assay was developed to be used in determining if PBMC from gilts that recovered from infection with an intra-nasal dose of PRRSV could reduce the number of PRRSV-infected MDM. Total PBMC from gilts with two different MHC haplotypes and four subpopulations including CD4 In addition, limited information on MHC class-I molecules presenting specific PRRSV epitopes hinder developing diverse MHC class-I-epitope-specific tetramers for rapid quantitation of PRRSV-specific T-cell responses. Even if pig MHC class-I-epitope-specific tetramers become available for PRRSV, tetramer-based quantitation is limited by the lack of information it provides about the function of positive cells and their protective efficacy. Therefore, developing functionally relevant CMI assays using natural target cells for PRRSV replication and the measurement of terminal effector function (e.g., virus suppression and/or cytolysis) as used in this study will be crucial for defining the protection correlates in PRRSV-infected and or vaccinated pigs.
Another important finding in this study is that on the day of PBMC collection, the three gilts with highly suppressive effector T-cells had weak and no detectable neutralizing antibody responses against challenge PRRSV SD23983 (1:4-1:16 virus neutralization titer) and a phylogenetically close PRRSV VR-2332 (<1:4), respectively [64] . This observation additionally suggests that PRRSV-specific CTL might be the major contributor for PRRSV control with no assistance of neutralizing antibodies. To extend these findings, the PRRSV epitopes recognized by the two different CTL phenotypes need to be defined and it needs to be determined whether these CTL are MHC class I-or class II restricted. For these new findings to impact vaccine strategies, it will be important to determine if the predominant CD4 
Materials and methods
Ethics statement
All experiments involving animals were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and in conformance with the United States Department of Agriculture animal research guidelines, under a protocol approved by the Washington State University Institutional Animal Care and Use Committee (ASAF # 04372-002).
Propagation and titration of PRRSV
The SD23983 strain of PRRSV (60) was propagated in the agent-free MARC-145 cell line (American Type Cell Collection, Manassas, VA, USA), cultured in complete Eagle's Modified Essential Medium (EMEM; Corning, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Seradigm, Radnor, PA, USA) at 37˚C. Confluent monolayers in 150 cm flasks were inoculated with a multiplicity of infection (MOI) of 0.01. When the virus-induced cytopathic effect (CPE) reached the maximum at 5 to 7 days, culture supernatants were collected and centrifuged at 4,000 × g for 10 minutes at 4˚C to eliminate cell debris.
The titer of PRRSV in each supernatant pool was determined using the microtitration infectivity assay [65] . The median tissue culture infective dose (TCID 50 ) was calculated according to the method of Reed and Munch http://ntserver1.wsulibs.wsu.edu:2091/science/article/pii/ S037811351200034X-bib0130 [66] . Briefly, confluent monolayers of MARC-145 cells, prepared in 96-well plates (Corning), were inoculated with 10-fold serial dilutions of PRRSV prepared in EMEM. The count of CPE present after seven days of culture was used to calculate the TCID 50 /mL.
PRRSV-infected and uninfected gilts used in this study
Five 12-month-old gilts (Sus scrofa domesticus) born from the same dam were selected and tested by PCR and or indirect immunofluorescent antibody to verify they were free of PRRSV, porcine circovirus type-2, porcine epidemic diarrhea virus and other major porcine pathogens. Three of the five gilts (gilt-1, gilt-2, gilt-3) were intra-nasally infected with 1.58 x 10 4 TCID 50 of PRRSV SD23983 and were maintained in isolation rooms. The infected gilts were the source of PBMC for the virus suppression and CTL assays reported in this study. The other two gilts (gilt-676 and gilt-678) were kept in a separate room to serve as a source of uninfected MHCmatched heterologous monocyte derived macrophage target cells.
MHC class I and II typing of gilts
Each of five gilts used in this study were genotyped for three swine leukocyte antigen (SLA) class I (SLA-1, -2, -3) and three SLA class II (DRB1, DQB1, DQA) genes using the low-resolution (Lr) polymerase chain reaction with sequence-specific primer (PCR-SSP) typing panels as previously described [67, 68] . SLA class I and class II haplotypes were deduced based on the published (15713212, 16305679, 18760302, 19317739) and unpublished haplotypes identified in outbred commercial pigs (http://www.jimmunol.org/cgi/content/meeting_abstract/186/1_ MeetingAbstracts/170.1). Gilts 676, 1 and 3 had a fully-matched set of SLA class I and II haplotypes (Table 1) . Gilts 678 and 2 had another fully-matched set of SLA class I and II haplotypes (Table 1) .
Preparation and storage of PBMC
Swine PBMC were isolated from fresh venous blood collected in 5 mM EDTA (final concentration) by centrifugation on a discontinuous gradient using Lymphoprep™ (STEMCELL Technologies, Vancouver, Canada) [52] . Briefly, blood in 5 mM EDTA was diluted two-fold in Table 1 . Major histocompatibility complex (MHC) genotypes of gilts used in this study. Genotypes in this table were determined for three swine leukocyte antigen class I (SLA-1, -2, -3) and three class II (DRB1, DQB1, DQA) genes using the low-resolution (Lr) polymerase chain reaction with sequence-specific primer typing panels.
PRRSV challenge MHC class I haplotype MHC class II haplotype MHC matching
Gilt
https://doi.org/10.1371/journal.pone.0203482.t001
10mM phosphate-buffered saline (PBS, pH 7.4) containing 20% anti-coagulant citrate dextrose (ACD) and 2% FBS. Thirty-five milliliters of the diluted blood was added to a SepMate™-50 tube (STEMCELL Technologies) containing 15 mL of Lymphoprep™. The tubes were centrifuged at 1,100 × g for 10 minutes. The buffy coat cells, at the supernatant cell interface, were collected and pelleted by centrifugation. The cells were resuspended in PBS containing 20% ACD and 2% FBS, and subjected to cycles of centrifugation until platelets were removed. Isolated PBMCs were counted, resuspended in a freezing medium containing 10% dimethyl sulfoxide (J.T. Baker, Center Valley, PA, USA) and 90% FBS, and stored in liquid nitrogen until used.
Preparation of monocyte-derived macrophages (MDM)
Frozen PBMC were thawed, washed with serum-free EMEM (Corning, Manassas, VA, USA), and incubated in serum-free EMEM at 37 o C for 2 hours in 100 cm petri dishes. The culture medium and non-adherent cells were discarded. The adherent cells were cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS and 5 ng/ ml of murine macrophage-colony stimulating factor (Biolegend, San Diego, CA, USA) every other day for 6 days. Six-day-old MDM were used as the target cells for virus suppression and CTL assays. MDM pulsed with heat inactivated PRRSV were used to stimulate a recall response in PBMC obtained from gilts that had recovered from infection.
Preparation of PRRSV-specific T-cell-enriched PBMC
PRRSV-specific T-cell-enriched cultures were generated by modification of a previously described method [52] . Briefly, six-day cultures of MDM prepared in 150 cm 2 tissue culture flasks were pulsed with heat-inactivated PRRSV for two hours. PBMC were resuspended to make 10 6 cells per ml in 40 ml, then added to the flask with heat-inactivated PRRSV-pulsed MDM and cultured for 7 days in RPMI-1640 medium supplemented with 10% of FBS and 5 ng/ml of recombinant porcine IL-7 (R&D Systems, Minneapolis, MN, USA). 
Positive and negative selection of T-cell subpopulations in PBMC
Virus suppression assay
The virus suppression assay (VSA) measured the reduction of PRRSV replication in MDM by PRRSV-specific T-cells and their subpopulations. MDM target cells were generated from PBMC of gilts that had recovered from clinical infection (source of autologous target cells), as well as from PBMC of PRRSV-free gilts (source of MHC-matched heterologous targets). In a preliminary validation experiment, 6-day cultured MDMs were highly susceptible for PRRSV infection (supporting data Fig 1) and stable that are critical features for target cells in VSA and cytotoxicity assay. Six-day cultures of MDM were harvested using a cell dissociation solution [69] as observed in other virus-infected targets such as simian immunodeficiency virus-infected CD4 T-cells [44, 45] . The percent reduction of infected MDM was calculated as evidence for the suppression of PRRSV replication by effector T-cells. Highly effective virus suppression was defined as 80% or more reduction of PRRSV-infected MDM in the presence of effectors as compared to target cells alone. The rationale for using a very low MOI (0.00005) of PRRSV in this VSA is to detect CTL responses sensitively in a physiologically more relevant condition to natural PRRSV infection to pigs.
CTL assay
A flow cytometric CTL assay was designed to measure the killing of PRRSV-infected MDM by CTLs. Target MDM cells were generated from PBMC of gilts that had recovered from PRRSVinfection as described above (autologous target cells), as well as PBMC from PRRSV-free gilts (MHC-matched heterologous target cells). Six-day cultures of MDM in cMEM were infected with 19.3 MOI of PRRSV and cultured for 0, 3, 6, 12, 18 and 24 hours. Any remaining PRRSV in the culture medium after incubation were removed by washing with PBS (pH 7.4). PRRSVinfected MDM were labelled with TFL4, a fluorescent permeable viable dye to distinguish live target cells from effector cells, per manufacturer's protocol (OncoImmunin Inc., Gaithersburg, MD, USA). The TFL4-labelled MDM were washed to remove excess dye and then incubated with total PBMC or T-cell subpopulations for 0, 3, 6, 12, 18 and 24 hours. At the designated time points MDM were brought into suspension and then pelleted by centrifugation at 800 x g for 10 minutes. The effector to target ratio was 5:1 (0.5 x 10 6 effectors and 0.1 x 10 6 MDM). 
